NCT05038488: A reported trial by Metro International Biotech, LLC
This trial has reported on time, in line with the regulations.
Full data
| Full entry on ClinicalTrials.gov | NCT05038488 |
|---|---|
| Title | A Phase 2a Randomized Controlled Trial of MIB-626 (NAD-boosting Drug) vs. Placebo in Adults With COVID-19 Infection and Early Acute Kidney Injury |
| Results Status | Reported |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Oct. 26, 2021 |
| Completion date | Aug. 17, 2023 |
| Required reporting date | Aug. 17, 2026, midnight |
| Actual reporting date | Feb. 19, 2025 |
| Date last checked at ClinicalTrials.gov | Oct. 29, 2026 |
| Days late | None |